89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology's annual scientific session together with world congress of cardiology

– post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with shtg regardless of their background lipid-modifying therapy status –
ETNB Ratings Summary
ETNB Quant Ranking